Quotient Limited Announces Details of Investor Day

JERSEY, Channel Islands, July 16, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today.

Following the recent announcement of positive field trial data in a European field trial, the Company met earlier today with investors and analysts at NASDAQ’s headquarters to provide an update on the progress towards the commercialization of MosaiQ.  Information presented included a demonstration of the features of the MosaiQ instrument designed to bring automated high throughput microarray based diagnostic testing to transfusion diagnostics and beyond. Franz Walt, Quotient’s CEO, presented the Quotient strategy for MosaiQ and the unique opportunity in the large transfusion diagnostics market. In addition, a voice of customer video described that market’s urgent need for innovation.  Jeremy Stackawitz, the Company’s President of Commercial, explained how MosaiQ’s unique product design is expected to meet the stated need of customers in an affordable automated format designed to deliver value through a reduction in the total cost of ownership when compared to currently available solutions. Ed Farrell, the Company’s President of R&D and Manufacturing, explained the unique aspects of the MosaiQ technology platform that should permit it to meet the needs of its chosen markets, while limiting the ability of competitors to replicate it.  Chris Lindop, Quotient’s CFO, closed by presented the expected business case for MosaiQ once it is commercially available, after which management took questions from those in attendance.

Franz Walt, Quotient’s CEO, commented, “I really believe in the power of the MosaiQ platform to transform not only transfusion diagnostics but also the wider diagnostics market, with its innovative automated microarray multiplexing technology. I think that this idea resonates with both customers and investors, who understand well the need for a game changing technology in these markets.”

A replay of the event will be available on the Company’s website, www.quotientbd.com.

MosaiQ Platform

MosaiQ, Quotient's next-generation platform delivers fast, comprehensive antigen typing, antibody detection and disease screening results, using a single low volume sample in a high throughput automated format. MosaiQ represents a transformative and highly disruptive unified testing platform for transfusion diagnostics. Feasibility has also been demonstrated with respect to the detection of nucleic acids (DNA or RNA) using the MosaiQ platform. Through MosaiQ, Quotient expects to deliver substantial value to donor testing laboratories worldwide by providing affordable, routine comprehensive characterization and screening of blood products, on a single automated instrument platform designed to radically reduce labor costs and complexity associated with existing practice.

About Quotient Limited

Quotient is a commercial-stage diagnostics company committed to reducing healthcare costs and improving patient care through the provision of innovative tests within established markets. With an initial focus on blood grouping and serological disease screening, Quotient is developing its proprietary MosaiQ™ technology platform to offer a breadth of tests that is unmatched by existing commercially available transfusion diagnostic instrument platforms. The company's operations are based in Edinburgh, Scotland; Eysins, Switzerland and Newtown, Pennsylvania.

The Quotient logo and MosaiQ™ are registered trademarks or trademarks of Quotient Limited and its subsidiaries in various jurisdictions.

CONTACT:Christopher Lindop, Chief Financial Officer - chris.lindop@quotientbd.com; +41 799 61 69 38

Primary Logo

Source: Quotient Limited